Endocrine Research Updates

For Medical Professionals

The 2017 guidelines, issued after 6 years of new evidence and experience, offer more targeted recommendations for clinical management of women who have thyroid disease once they become pregnant as well as postpartum. Four key changes in the new guidelines are highlighted.
Elevating the predictive accuracy of biopsy node assessment may be possible using both a highly specific oncogene panel and a classification test for miRNA gene expression to improve surgical decision-making.
Improving sleep by adjusting work-shifts to fit a person's chronotype may be the most effective approach to address resistant diabetes or creeping obesity.
To provide the most effective care for patients with diabetes, EndocrineWeb editorial board members consider the barriers to care from individualized care planning and a change to prevention over fee-for-serve care, to integrating obesity strategies into diabetes management.
When surgery is not an option for hyperparathyroid disease, try thiazides.
When surgery is not an option, thiazide diuretics--an old drug class with complicated side effects--may offer an effective alternative for some patients.
Annual review of standards has many firsts, including the need to individualize treatment with a focus on staging diabetes; addressing obesity, sleep, mental health; and, accounting for patient costs in treatment to achieve the best outcomes for people at risk of or having diabetes.
Cannabis is known to have a positive role in reducing pain but its effect on metabolism and the endocrine system appear less favorable. Researchers examined the use of cannabis in thyroid function, finding a significantly elevated TSH among current users who were typically young males whose risk of thyroid or diabetes is low.
With 9 endpoints of gastric, metabolic and bariatric surgeries identified, clinicians will have targeted results to utilize in guiding patients in the selection or avoidance of invasive weight loss procedures.
In promoting a patient-centered approach to diabetes care, endocrinologists are urged to assess mental state of patients as a means to better outcomes.
Guidelines to foster better risk assessment for bone fracture, and more aggressive strategies for osteoporosis inpatients on glucocorticoid therapy
Clinicians may have clear markers to guide prescribing decisions with regard to those at highest risk of developing diabetes—a risk that appears to be very low for most, but not all.
Clinicians have 2 clear markers that may predict who's at highest risk of developing diabetes:
Clinicians should follow women who develop gestational diabetes and intervene early to reduce risk for cardiovascular diseases.
Clinical Practice for Iodine Supplementation during Preconception, Pregnancy, and Lactation Lags Behind Medical Society Recommendations
Iodine supplementation for women of childbearing age, pregnancy and breastfeeding is recommended but 3 in 4 practitioners do not followed the prescribed recommendations.
Non-Invasive Imaging may reduce need for removal of benign thyroid nodules.
Using FDG-PET in combination with sonographic features may improve diagnosis of indeterminate thyroid nodules that are benign, aiming for fewer surgeries.
Researchers found that Sitagliptin and Metformin therapy may prevent hyperglycemic relapses in obese African Americans
Treatment with pioglitazone, a thiazolidinedione, acts as a preventive agent in individuals with insulin sensitivity who are at elevated risk for cardiovascular disease.
Results may needlessly worry some, researcher says; others call it an urgent need to alert Americans early and get them the medical care necessary to avoid costly care later
Despite the known efficacy and value, the range of available weight loss medications remain underutilized and inadequately prescribed
Scientific consensus demands action to protect the public from the known adverse impact of commonly occurring, endocrine-disrupting chemicals (EDCs) found in the environment.
new weight loss device prompts sustained weight loss
Reduced comorbid risk factors and improved satiety reported with minimal side effects, using the first new obesity therapy to receive FDA device approval in 9 years